Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $66.6667.

A number of equities research analysts have recently commented on RVPH shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. D. Boral Capital downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, March 14th. Finally, Chardan Capital reissued a “buy” rating and set a $40.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals during the 1st quarter valued at $58,000. XTX Topco Ltd lifted its position in shares of Reviva Pharmaceuticals by 63.6% during the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after buying an additional 63,893 shares during the last quarter. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth $37,000. Finally, Millennium Management LLC grew its stake in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the period. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Stock Performance

Shares of Reviva Pharmaceuticals stock opened at $0.72 on Monday. The business’s fifty day simple moving average is $3.67 and its 200 day simple moving average is $7.63. Reviva Pharmaceuticals has a 12 month low of $0.59 and a 12 month high of $23.20. The firm has a market capitalization of $9.22 million, a P/E ratio of -0.08 and a beta of 0.64.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.